Figure 1
Figure 1. Derivation of hematopoietic cells from hESCs suitable for clinic therapies. Both hESCs derived from preimplantation blastocysts and iPSCs produced from somatic cells by gene transfer and/or chemical treatment can be used to investigate blood cell development. Two main methods have been used to produce hematopoietic cells from hESCs and iPSCs: embryoid body formation and stromal cell coculture. In vitro and in vivo studies have shown the development of essentially all mature hematopoietic cell populations from hESCs, with similar studies using human iPSCs being under way. The boxes around RBCs, platelets, and NK cells suggest these to be the most promising cell lineages to take into clinical trials, based on current status of the field.

Derivation of hematopoietic cells from hESCs suitable for clinic therapies. Both hESCs derived from preimplantation blastocysts and iPSCs produced from somatic cells by gene transfer and/or chemical treatment can be used to investigate blood cell development. Two main methods have been used to produce hematopoietic cells from hESCs and iPSCs: embryoid body formation and stromal cell coculture. In vitro and in vivo studies have shown the development of essentially all mature hematopoietic cell populations from hESCs, with similar studies using human iPSCs being under way. The boxes around RBCs, platelets, and NK cells suggest these to be the most promising cell lineages to take into clinical trials, based on current status of the field.

Close Modal

or Create an Account

Close Modal
Close Modal